Glasdegib (PF-04449913), another SMO inhibitor that has demonstrated potent and selective inhibition of Hedgehog signaling in vitro, and significant antitumor efficacy in vivo in various solid and hematologic malignancies [93], is a rational therapeutic agent currently in phase I/II for patients with newly diagnosed GBM, since it inhibits SHH pathway interfering with cancer stem cells and endothelial migration. The gene discussed is SMO; the disease is cancer.